Back to results
US 12,257,290 B2Granted
PIC1 inhibition of myeloperoxidase oxidative activity in an animal model
AssigneeRealta Holdings, LLC
InventorsNeel K. Krishna, Kenji Cunnion
Life of this patent
Estimating the term…
Abstract
A method of treating systemic lupus erythematosus in a subject is provided in which a therapeutically effective amount of PIC1 is administered to the subject. A method of treating transfusion-related acute lung injury is also provided where a therapeutically effective amount of PIC1 is administered to the subject. PIC1 can modulate immune complex activation of the complement system and NET formation in the subject. PIC1 can also inhibit myeloperoxidase (MPO) activity in the subject.
Claims10
A method of reducing myeloperoxidase (MPO) levels in a subject, the method comprising:
- administering a therapeutically effective amount of a PIC1 peptide to the subject in need thereof, wherein the PIC1 peptide comprises the sequence of IALILEPICCQERAA-dPEG24 (SEQ ID NO:
- 19),
- wherein the PIC1 peptide is administered at a dose of from 5 to 160 mg/kg body weight of the subject.
Dependencies are inferred from the claim text.